At CHM, our mission is to grow pharmaceutical brands by elevating health literacy in underserved multicultural patient communities.
We are the leaders in community health education. Your brand benefits through our unrivaled network of HCPs and media, decades of health insights across multiple cultures, profound expertise managing pharmaceutical brands, and the efficiency stemming from our understanding of relevant FDA promotional regulations.
CHM is 100% minority & woman owned.
culturally resonant, community
engagement is at the
heart of what we do.
Powered by CHM’s Community Connection Platform™
Community Connection™ provides turnkey access to community HCPs and underserved patients, including those from Asian American and Hispanic communities, to facilitate the delivery of relevant health information.
The CHM Community Connection™ Platform allows us to provide the services our clients need in a structure that is turnkey, efficient, and effective.
This 360-degree approach drives authentic community engagement and impressive results for our clients.
Authentic, results-driven outreach and engagement to these communities takes a multi‑disciplinary approach and a multi‑pronged strategy to build trust and credibility with patients, HCPs who treat them, and community activists who defend and protect them.
It’s not just about
language, it’s about
a true connection to
We grew up in the communities our brands serve. Our partners and friends thrive there, today. This intimacy empowers us to deliver real results for those brands and for the lives that depend on them.
We have a proven track record of success in providing:
Branded & Unbranded Community Outreach
& HCP Engagement
PR & Advocacy
Research, Data Analytics,
Our clients enjoy high-ROI results while our communities receive authentic, culturally-resonant, in-language engagement.
What community thought leaders say about us:
And the industry has taken notice:
Ad Age Multicultural
DTC National Awards
DTC 2019 Nominee
Best Outdoor, PR or Event
Clients we introduced to our communities:
Eileen understands from personal experience just how challenging language and culture barriers can be, both for underserved patients and their doctors. She came to the United States at an early age as a refugee from Burma (Myanmar) and took on the role of health advocate for her family members.
After acquiring a BA with honors in Biology from Barnard College, and an MBA from Columbia Business School, she entered the world of pharmaceutical marketing on the client-side.
She spent over 15 years as a marketing leader building, launching and growing Hepatitis, CV/Diabetes, Oncology, and Dermatology brands. Since 2011, she’s put that knowledge to work on the agency-side at CHM with a focus on creating genuine connections between brands, patients, and physicians.
Chief Operating Officer
As a leader at CHM, Kim satisfies her need to bring innovative ideas to life and to break down communication barriers which lead to better health outcomes. She is a strategic expert that has spent the majority of her career in Healthcare entrepreneurship, leading brand teams and agencies across a wide range of therapeutic areas including Oncology, GI, Vaccines, RA, MS, Respiratory, CNS, Women’s Health, Urology, Pain Management, Dermatology, Smoking Cessation, Depression, CV, & Diabetes.
Kim is a first generation Hispanic who is passionate about helping underserved communities, and about leveraging technology to improve the health outcomes of all members of our society.
Kim holds an MBA from The Wharton School of Business with dual majors in Marketing and Entrepreneurial Management.
Brand team marketing a mature brand had maxed-out growth with a General Market (GM) strategy and was looking for new growth opportunities.
ROIs on programs that ranged from 20:1 to 8:1; A&I research showed dramatic increases in patient awareness and intent from Wave #1.
Brand team was launching a drug in a crowded space with a dominant #1 and was struggling to identify a winning strategy.
Doubled market share in the 1st year after pivoting to the new multicultural strategy.
Brand team launching in a crowded marketplace, decided to go after a new indication to enter the Immunotherapy market, but recruiting was crawling to a halt for their Phase 2 trial.
Doubled enrollment allowing to close enrollment ahead of schedule after pivoting to the new multicultural recruitment strategy.
Brand team followed traditional General Market (GM) launch protocol and saw lackluster market performance.
5% – 30% brand sales growth within 1st year, double-digit brand sales growth after initial launch of CHM campaign; 6:1 ROI.